Welcome to the Website of “Forum for Maruyama Vaccine & Cancer,” a Specified Nonprofit Organization.
This website introduces Specific Substance MARUYAMA (SSM, commonly called Maruyama Vaccine), which has been playing a pioneering role in cancer immunotherapy. Highly technical references such as research papers that have been published or submitted on the effectiveness of cancer therapy using SSM are currently posted in the English pages of this website.
SSM has been administered to approximately 390,000 patients as an investigational new drug for cancer treatment and has demonstrated a number of positive outcomes.
SSM awakens the immune system in humans and encourages production of cytokines such as interferon through activation of lymphocytes and other elements.
SSM also increases collagen. By continuing to inject SSM, collagen fibers build up around cancer cells, encircling them and causing cancer cells to become dormant. Sometimes cancer is shrunk or reduced, which indirectly blocks cancer growth and causes it to self-destruct.
With a history of over 45 years of use in medical practice, SSM’s five characteristic effects have been confirmed through clinical studies and research.
1. No adverse side effects.
2. Superior survival prolongation.
3. Subjective symptoms relief.
4. Cancer shrinkage/disappearance.
5. Suppression of cancer growth/metastasis.
<English archives>
- The Generation of the Maruyama Vaccine (Specific Substance of Mycobacterium=SSM) and its Application to Medical Treatment
- Collagen and Stromal Proliferation as Preventive Mechanisms Against Cancer Invasion by Purified Polysaccharides From Human Tubercle Bacillus (SSM)
- Collagen Fiber Formation and Proliferation as a Mechanism of Cancer Prevention and Regression Induced by Extract From Mycobacterium Tuberculosis: Correlation Between Clinical Observation and Animal Experiments
- On the Treatment of Malignant Tumor with an Extract Tubercle Bacilli (Tubercle Vaccine)
- Co-operation of Innate and Acquired Immunity for Controlling Tumor Cells